UroToday3h
ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma
(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...
UroToday3h
EAU 2023: 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma - Results from Phase 3 ZIRCON Study
(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10 th and 13 th, 2023 was host to a game changing session. Professor Peter Mulders ...
UroToday23h
SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting
(UroToday.com) The 2024 SUO annual meeting included a session on smoking cessation, vaping, and e-cigarettes, featuring a presentation by Dr. Richard Matulewicz discussing implementing smoking ...
UroToday23h
ASCO 2024: Blood-Based Markers of Differential Efficacy of Bipolar Androgen Therapy and Enzalutamide in the Randomized TRANSFORMER Trial
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between May 31 and June 4 was host to the Rapid Oral Abstract Session: Genitourinary Cancer - ...
UroToday23h
SUO 2024: Heterogeneity of Intermediate Risk NMIBC
(UroToday.com) The 2024 SUO annual meeting included a session on non muscle invasive bladder cancer (NMIBC), featuring a presentation by Dr. Sima Porten discussing the heterogeneity of intermediate ...